Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,543 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06203496Recruiting
Monitoring brain tumors with blood tests
This trial studies whether a blood test can track the progress of a type of brain tumor called a grade 4 diffuse glioma. It may offer a less invasive way to monitor these tumors after surgery.
CaenAges 18 years+ - NCT07865793RecruitingPhase 2
Lattice radiation with immunotherapy for advanced tumors
This trial tests a new way to give radiation called lattice therapy together with immunotherapy drugs that help your immune system fight cancer. It is for people with advanced solid tumors that have grown or spread, with at least one large tumor that can be measured.
Shenzhen, GuangdongAges 18–70 - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT06219096Recruiting
Using a dye to guide liver tumor surgery with a camera
This trial tests a new way to help surgeons see liver tumors more clearly during keyhole (laparoscopic) surgery. A special dye (ICG) is used with a camera to guide the surgeon in removing just the right part of the liver. It may lead to safer and more precise surgery for people with liver cancer.
Chengdu, SichuanAges 18–75 - NCT05695638Recruiting
Genetic tumor testing to find treatments for advanced cancer
This study looks at your tumor’s genetic information to help match you to targeted treatments when standard options are no longer working. You may be offered options based on results, with the goal of helping people with incurable, worsening cancer.
AalborgAges 18 years+ - NCT03838042RecruitingPhase 1/Phase 2
Testing nivolumab plus entinostat for high-risk childhood cancers
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
Randwick, New South WalesAges 2–21 - NCT06250595Recruiting
European rare blood disorder registry
This study is building a registry of people with rare blood diseases. By joining, you help doctors learn more about these conditions and improve future care.
Barcelona, CataloniaAges Up to 100 years - NCT07857746Recruiting
Outcomes of stem cell transplant in children
This study looks at how children who received a stem cell transplant at one hospital are doing. It aims to learn about their recovery and long-term results, which can help improve care for future patients.
Ratchathewi, BangkokAges Up to 18 years - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06286631Recruiting
Predicting lymph node spread in thyroid cancer with a new scale
This trial is testing a new scale to predict if thyroid cancer has spread to nearby lymph nodes. It may help doctors decide on the best treatment for you.
Xi'an, ShaanxiAges 16–80 - NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05389956Recruiting
Study links health screening results to heart and cancer risk
This study follows people who had a routine health check to learn what increases the risk of heart disease and cancer. Your answers and test results may help doctors better understand risk factors in the Korean population.
UlsanAges 19 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT05217407Recruiting
Registry study for people with rare or advanced cancers
This is a study that collects information about people with rare cancers (or cancers where the source is unknown) and advanced-stage cancer. It helps researchers build a knowledge database to improve understanding and care for these cancers in Asia.
Chuo-ku, TokyoAges 18 years+ - NCT06338332Recruiting
Stent before surgery for right-sided colon blockage from cancer
This trial tests whether placing a stent first to relieve a blockage in the right side of the colon improves outcomes before surgery for colon cancer. It aims to help patients who come to the hospital with a blocked colon due to cancer.
Breda, North BrabantAges 18 years+ - NCT05678621RecruitingPhase 2/Phase 3
Testing stopping or extending immune treatment to prevent infections
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06375161RecruitingEarly Phase 1
CAR-T cells for relapsed B-cell cancers
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
Shanghai, Shanghai MunicipalityAges 4 months–1.3 years - NCT06381726Recruiting
Personalized brain mapping to protect movement during glioma surgery
This study tests a personalized approach to map and protect the brain's movement pathways during surgery for slow-growing brain tumors. The goal is to remove as much tumor as possible while keeping your quality of life and movement abilities intact.
Milan, LombardyAges 18 years+ - NCT05539677Recruiting
Research biobank and patient registry for aggressive solid tumors
This study builds a biobank and patient registry using tumor samples and blood. It helps researchers better understand aggressive cancers and may improve future treatments by testing immune (defense) responses.
Saint PetersburgAges 1 year+ - NCT06410092RecruitingPhase 1
Safety study of FTL001 for advanced solid tumors
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18–75 - NCT06416761Recruiting
Genetics and kidney disease progression study
This study looks at how genetics affect the progression of kidney diseases. Joining may help researchers understand your condition better and find better treatments.
MilanAges 18 years+ - NCT07849088RecruitingPhase 2
Chinese herbal medicine to protect kidneys during radiation therapy
This study tests a traditional Chinese herbal medicine (called Zhixiao Tongmai Ning) to see if it can protect your kidneys from damage caused by radiation therapy. If you have kidney cancer and are receiving radiation, this treatment might help keep your healthy kidney tissue working better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07847359RecruitingPhase 2
Freezing and drug combination for melanoma that has spread to the liver
This trial tests a combination of treatments for melanoma that has spread to the liver after standard treatment. It uses freezing (cryoablation), a targeted drug (lenvatinib), chemotherapy (dacarbazine), and two immunotherapy drugs to try to shrink liver tumors and control the cancer. The goal is to see if this combined approach is safe and effective for patients whose cancer has not responded to prior therapy.
Guangzhou, GuangdongAges 18–75 - NCT07844694RecruitingPhase 1
Low-dose sirolimus for patients with RUNX1 platelet disorder
This trial tests whether a low dose of sirolimus, a drug that calms the immune system, can help improve blood counts and reduce bleeding risk in people with a genetic condition called RUNX1 familial platelet disorder. If it works, it might lower the chance of developing serious blood problems later.
Portland, OregonAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,543 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.